PARP inhibitors (PARPi) have shown promise in treating acute myeloid leukemia (AML) and other blood cancers, particularly in cases with specific genetic alterations such as RUNX1-RUNX1T1, PML-RARA, FLT3, and IDH1/2 mutations 32. Here, IDH1 is linked to hematopoietic and lymphoid system neoplasm.